Compare BY & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BY | EYPT |
|---|---|---|
| Founded | 1914 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2017 | 2005 |
| Metric | BY | EYPT |
|---|---|---|
| Price | $29.52 | $18.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $33.67 | $29.60 |
| AVG Volume (30 Days) | 196.7K | ★ 1.3M |
| Earning Date | 01-22-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ 1.54 | N/A |
| EPS | ★ 2.80 | N/A |
| Revenue | ★ $400,663,000.00 | $42,339,000.00 |
| Revenue This Year | $19.64 | N/A |
| Revenue Next Year | $3.98 | N/A |
| P/E Ratio | $10.61 | ★ N/A |
| Revenue Growth | ★ 7.23 | N/A |
| 52 Week Low | $22.63 | $3.91 |
| 52 Week High | $31.24 | $19.11 |
| Indicator | BY | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 64.35 |
| Support Level | $29.72 | $16.52 |
| Resistance Level | $31.00 | $19.00 |
| Average True Range (ATR) | 0.54 | 0.96 |
| MACD | -0.17 | 0.03 |
| Stochastic Oscillator | 11.63 | 70.53 |
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.